ReproCell Inc
TSE:4978
ReproCell Inc
Cost of Revenue
ReproCell Inc
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ReproCell Inc
TSE:4978
|
Cost of Revenue
-¥1.4B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-21%
|
|
GNI Group Ltd
TSE:2160
|
Cost of Revenue
-¥3.6B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-36%
|
|
PeptiDream Inc
TSE:4587
|
Cost of Revenue
-¥11.5B
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
Takara Bio Inc
TSE:4974
|
Cost of Revenue
-¥21.3B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Cost of Revenue
-¥13.1B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
-35%
|
|
S
|
StemRIM Inc
TSE:4599
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ReproCell Inc's Cost of Revenue?
Cost of Revenue
-1.4B
JPY
Based on the financial report for Dec 31, 2023, ReproCell Inc's Cost of Revenue amounts to -1.4B JPY.
What is ReproCell Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-21%
Over the last year, the Cost of Revenue growth was 24%. The average annual Cost of Revenue growth rates for ReproCell Inc have been -26% over the past three years , -20% over the past five years , and -21% over the past ten years .